** Shares of vaccine maker Moderna MRNA.O fall 6.1% to $26.81
** Co pushes back the time frame for likely approval of a combination vaccine meant to protect against both COVID-19 and influenza
** "It's not directly clear how MRNA will be impacted by HHS (Department of Health and Human Services) requirements for placebo studies for "new" vaccines... Flu will not need placebo per HHS. But overall, changes by HHS bring uncertainty for the landscape and investors" - brokerage Jefferies
** MRNA posts Q1 adj loss of $2.52/shr, smaller than Wall Street estimates for a loss of $3.14/shr - LSEG
** Co brings in $108 mln in Q1 revenue, slightly ahead of analysts' expectations of $106.2 mln
** Including session's move, stock down 33.9% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。